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SUPPLEMENT

Pharmacological and Combined Interventions to Reduce
Vaccine Injection Pain in Children and Adults
Systematic Review and Meta-Analysis
Vibhuti Shah, FRCPC, MD, MSc,*w Anna Taddio, BScPhm, MSc, PhD,zy
C. Meghan McMurtry, PhD, C Psych,8z# Scott A. Halperin, MD,**
Melanie Noel, PhD,ww Rebecca Pillai Riddell, PhD, C Psych,yzz
Christine T. Chambers, PhD, RPsych,yy and HELPinKIDS Team

Background: This systematic review assessed the eﬀectiveness and
safety of pharmacotherapy and combined interventions for
reducing vaccine injection pain in individuals across the lifespan.
Design/Methods: Electronic databases were searched for relevant
randomized and quasi-randomized controlled trials. Self-reported
pain and fear as well as observer-rated distress were critically
important outcomes. Data were combined using standardized
mean diﬀerence (SMD) or relative risk with 95% conﬁdence
intervals (CI).
Results: Fifty-ﬁve studies that examined breastfeeding (which
combines sweet-tasting solution, holding, and sucking), topical
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anesthetics, sweet-tasting solutions (sucrose, glucose), vapocoolants, oral analgesics, and combination of 2 versus 1 intervention
were included. The following results report ﬁndings of analyses of
critical outcomes with the largest number of participants. Compared with control, acute distress was lower for infants breastfed:
(1) during vaccination (n = 792): SMD  1.78 (CI, 2.35,  1.22)
and (2) before vaccination (n = 100): SMD  1.43 (CI,  2.14,
 0.72). Compared with control/placebo, topical anesthetics
showed beneﬁt on acute distress in children (n = 1424): SMD
 0.91 (CI,  1.36,  0.47) and self-reported pain in adults
(n = 60): SMD  0.85 (CI,  1.38,  0.32). Acute and recovery
distress was lower for children who received sucrose (n = 2071):
SMD  0.76 (CI, 1.19, 0.34) or glucose (n = 818): SMD  0.69
(CI, 1.03, 0.35) compared with placebo/no treatment. Vapocoolants reduced acute pain in adults [(n = 185), SMD  0.78 (CI,
 1.08, 0.48)] but not children. Evidence from other needle
procedures showed no beneﬁt of acetaminophen or ibuprofen. The
administration of topical anesthetics before and breastfeeding
during vaccine injections showed mixed results when compared
with topical anesthetics alone. There were no additive beneﬁts of
combining glucose and non-nutritive sucking (paciﬁer) compared
with glucose or non-nutritive sucking (paciﬁer) alone or breastfeeding and sucrose compared with breastfeeding or sucrose alone.
Conclusions: Breastfeeding, topical anesthetics, sweet-tasting solutions, and combination of topical anesthetics and breastfeeding
demonstrated evidence of beneﬁt for reducing vaccine injection
pain in infants and children. In adults, limited data demonstrate
some beneﬁt of topical anesthetics and vapocoolants.
Key Words: pain management, randomized controlled trial, systematic review, vaccination

(Clin J Pain 2015;31:S38–S63)

T

he availability of vaccines has been a major breakthrough in the ﬁeld of medicine, and vaccination programs have been the most cost-eﬀective way of reducing the
burden of communicable diseases. Despite the proven
beneﬁts of vaccination, many individuals globally have not
reaped its beneﬁts. Therefore, as part of an on-going eﬀort
to improve vaccination rates, the World Health Organization and their partners have developed the “Global
Vaccination Action Plan” with the goal to improve vaccination compliance and reduce mortality from communicable diseases throughout an individual’s lifespan.1 As
more vaccines become available and incorporated into
vaccination schedules, individuals are subjected to an
increasing number of injections. Vaccine injections are the
Clin J Pain



Volume 31, Number 10S, October 2015

Clin J Pain



Volume 31, Number 10S, October 2015

most common source of iatrogenic pain in children and
adults and an important contributing factor to noncompliance with vaccination.2–4 Pain associated with vaccination is now recognized as an important adverse event
following immunization, and managing pain should therefore be part of every vaccination.5
Over the last several decades, numerous strategies
including pharmacological, physical, procedural, process,
and psychological interventions have been evaluated to
mitigate the pain from vaccine injections.6 Despite the
eﬀectiveness of many of these interventions, they are not
routinely used by health care providers in clinical practice.7
Pharmacological and combined interventions in particular,
are rarely used due to barriers to implementation such as
uncertainty about their eﬀectiveness, concerns regarding
adverse consequences, time commitment, and potential
cost.
In a previous systematic review published on this topic
in 2009,8 evidence was found to support several interventions that were then incorporated into a clinical practice
guideline for vaccination pain management in children.6
Since that analysis, new literature has been published,
including evaluation of combined interventions. Hence,
there was a need to update the review. In addition, the
previous synthesis was limited to children and it was
deemed necessary to expand the synthesis to adults.
Therefore, the HelpELiminatePain in KIDS (HELPinKIDS) team made a decision to expand the scope of the
synthesis to include the literature on adult populations
(HELPinKids&Adults).
The objective of this systematic review was to assess the
eﬀectiveness and safety of combined interventions and
pharmacotherapy in reducing the pain associated with vaccine injections in children and adults. The interventions
evaluated included: (1) breastfeeding (which combines sweettasting solution, sucking, and holding [physical comfort]),
either before or during vaccine injections; (2) topical anesthetics; (3) sweet-tasting solutions (sucrose and glucose); (4)
vapocoolants; (5) oral analgesics (acetaminophen and ibuprofen); and (6) 2 interventions versus 1 intervention (ie,
topical anesthetic and breastfeeding vs. topical anesthetics
alone; sweet-tasting solutions and non-nutritive sucking vs.
sweet-tasting solutions or non-nutritive sucking alone; or
sweet-tasting solutions and breastfeeding vs. breast feeding
or sweet-tasting solutions alone).

METHODS
The methodological details used to perform this systematic review are described elsewhere.9 In short, both the
Grading of Assessments, Recommendations, Development,
and Evaluation (GRADE)10 and Cochrane11 methodologies guided the review.

Search Strategy
A comprehensive literature search was performed
using the search strategy developed by the authors based on
their content expertise and in consultation with an academic librarian for the following databases: EMBASE,
Medline, PsycINFO, CINAHL, and ProQuest Dissertations & Theses Global (inception—February 26, 2015).
No language restrictions were applied. The titles and
abstracts of the articles were screened and retrieved articles
were assessed for eligibility by 2 reviewers (V.S., A.T.). In
Copyright
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addition, reference lists from eligible articles were reviewed
to identify additional studies.

Inclusion/Exclusion Criteria
This review included: (1) children and adults undergoing vaccine injections in any setting (eg, hospital, community) or if not undergoing vaccine injections, the closest
related needle procedure or context (eg, venipuncture,
venous cannulation, needle puncture into a subcutaneous
[SC] port); and (2) randomized controlled trials (RCTs) or
studies with a quasi-randomized study design. We included
studies published as full or short reports, as well as published academic theses. We excluded studies in which the
analgesic intervention or the outcome of interest was not
clearly deﬁned, published abstracts, letters, commentaries,
and editorials.

Clinical Questions
The included clinical questions and outcomes of
interest (Table 1) were prioritized by the HELPinKids&Adults team.

Outcomes of Interest
As per the GRADE methodology, outcomes of interest were categorized as critical and important outcomes for
inclusion in the review and data for these outcomes were
extracted from the eligible studies. The critically important
and important outcomes for included clinical questions are
shown in Table 1. Self-report of pain was prioritized as the
critically important outcome when self-report of pain was
possible (eg, child over 3 y of age). For children under 3
years, distress was the critically important outcome. Fear
was prioritized as a critical outcome only for topical anesthetics and required the ability to self-report.
For health care professionals, safety (adverse consequences), ﬁdelity, feasibility, and preference are major
issues that need to be addressed before implementing evidence-based interventions in practice. Therefore, the abovelisted outcomes were prioritized as important outcomes and
are included in the presentation of outcomes. For topical
local anesthetics, we examined transient changes in skin
color (pallor or erythema), edema and eﬀects on the
immune response. Episodes of aspiration, vomiting, cyanosis, and respiratory change during and after the procedure were assessed for breastfeeding; episodes of choking,
coughing, gagging, nausea, vomiting, and physiological
instability were assessed for sweet-tasting solutions (eg,
sucrose, glucose), and oral analgesics. For vapocoolants,
pain during application and skin reactions were evaluated.
Data on immunogenicity was examined for oral analgesics.
We also reported on the ﬁdelity (use or compliance with the
intervention), feasibility (ease of adoption in clinical practice), and preferences (choosing one intervention over the
other) for each of the intervention as available.

Quality Assessment
The methodologic quality of the studies was assessed
by 2 reviewers using the Cochrane Collaboration’s Risk of
Bias tool, and the overall summary assessment of the Risk
of Bias was designated for individual studies.11

Data Abstraction and Synthesis
Data were abstracted on a predesigned form by 2
reviewers (V.S., A.T.) and checked for accuracy. The trials
had to include the data necessary for pooling in a metaanalysis, such as means and standard deviations (SDs), and

2015 Wolters Kluwer Health, Inc. All rights reserved.
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TABLE 1. Clinical Questions and Outcomes

Critical
Outcomes*

Clinical Questions
Pharmacological interventions
Should breastfeeding be used during vaccine injections in
children 0-2 y?
If breastfeeding is not used during vaccine injections, should
breastfeeding be used before vaccine injections in children
0-2 y?
Should topical anesthetics be applied before vaccine injections
in children 0-12 y?

Distress
Distress
Pain, distress,
fear

Should topical anesthetics be applied before vaccine injections
in adolescents >12 y and adults?

Pain

Should topical anesthetics be used before vaccine injections in
combination with breastfeeding during vaccine injections
(rather than topical anesthetics or breastfeeding alone) in
children 0-2 y?
Should sucrose solution be given before vaccine injections in
children 0-2 y?
Should glucose solution be given before vaccine injections in
children 0-2 y?
Should sweet-tasting solutions (sucrose, glucose) be used before
vaccine injections in combination with non-nutritive sucking
(ﬁnger/thumb, paciﬁer) during vaccine injections (rather than
sweet-tasting solutions or non-nutritive sucking alone) in
children 0-2 y?
Should breastfeeding and sweet-tasting solutions (sucrose,
glucose) be combined together before vaccine injections
(rather than breastfeeding or sweet-tasting solutions alone) in
children 0-2 y?
Should vapocoolants be applied before vaccine injections in
children 0-3 y?
Should vapocoolants be applied before vaccine injections in
children >3-17 y?

Distress

Should vapocoolants be applied before vaccine injections in
adults?
Should acetaminophen be given before vaccine injections in
individuals of all ages?
Should ibuprofen be given before vaccine injections in
individuals of all ages?

Distress
Distress
Distress

Important Outcomes
Procedure outcome, safety, parent fear, use of
intervention, compliance, preference, satisfaction
Procedure outcome, parent fear, use of intervention,
compliance, preference, satisfaction
Procedure outcome, safety, parent fear, use of
intervention, compliance, memory, preference,
satisfaction
Distress, fear, procedure outcome, safety, use of
intervention, compliance, memory, preference,
satisfaction
Procedure outcome, safety, parent fear, use of
intervention, compliance, preference, satisfaction
Procedure outcome, safety, parent fear, use of
intervention, compliance, preference, satisfaction
Procedure outcome, safety, parent fear, use of
intervention, compliance, preference, satisfaction
Procedure outcome, safety, parent fear, use of
intervention, compliance, preference, satisfaction

Distress

Procedure outcome, safety, parent fear, use of
intervention, compliance, preference, satisfaction

Distress

Pain, distress

Parent fear, procedure outcome, safety, compliance,
preference, satisfaction
Distress, fear, parent fear, procedure outcome,
safety, compliance, memory, preference,
satisfaction
Distress, fear, procedure outcome, safety,
compliance, memory, preference, satisfaction
Fear, safety, compliance, preference, satisfaction

Pain, distress

Fear, safety, compliance, preference, satisfaction

Pain
Pain

*Distress is the critical outcome in the absence of data for pain, fear, or both in individuals incapable of self-report (eg, infants).

the prioritized outcomes had to be assessed by the child or
adult (self-report) or by others using validated tools.12,13
Modiﬁcation of the original data was done as needed
on a predeﬁned, restricted basis according to established
methods.14 For example, means (and SDs) were calculated
from medians, ranges, and 95% conﬁdence intervals (CIs),
or estimated from graphs.14 As pain, distress, or both were
assessed at multiple timepoints in the included studies, the
data were standardized and analyzed as follows (according
to the procedure phase): (1) the preprocedure phase, which
occurred postintervention but before vaccine injection(s);
(2) the acute procedure phase (within the ﬁrst minute of
needle puncture and vaccine injection); and (3) the recovery
procedure phase (1 to 5 min after vaccine injection(s)) to
determine the eﬀectiveness of an intervention.
Established methods were used to pool data before
inclusion in the meta-analysis if data were available from
multiple observers evaluating the same outcome (eg,
parent-rated or clinician/researcher-rated child distress) or
if available at multiple timepoints within the same

S40 | www.clinicalpain.com

procedure phase (eg, acute distress measured every 15 s
within the ﬁrst minute of vaccine injection).15 The scores
were ﬁrst standard on a scale of 0 to 10, using an estimated
correlation of 0.25.16 This process allowed all the data
pertaining to an outcome to contribute to the summary
statistic included in the meta-analysis and reduce bias from
either “selecting/picking the data” from individual studies
included in the meta-analysis.9 Authors of trials were contacted for further details or provision of original data if the
published report contained insuﬃcient information. Missing data were not imputed.
All statistical analyses were conducted using Review
Manager (RevMan) version 5.2, the statistical software
provided by the Cochrane Collaboration (Copenhagen,
Denmark).11 Results are presented as standardized mean
diﬀerence (SMD) and 95% CI or relative risk (RR) and
95% CI as appropriate. All meta-analyses were conducted
using a random-eﬀects model. Statistical heterogeneity was
assessed using I2 and w2 tests.11 If appropriate, a sensitivity
analysis was performed by including and excluding studies

Copyright
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Identification

Records identified through
database searching
(n = 114,251)

Additional records identified
through other sources
(n = 138)

Total records retrieved
(n = 114,389)

Screening

Duplicate references
(n = 32,155)

Included

Screened for eligibility
(n = 82,234)

Studies included in
systematic review
(n = 55)

Full-text articles excluded
due to head-to-head
comparison, combined
intervention, intervention
differs from clinical
question, inadequate
reporting of study details
(n = 5)
The remainder were not
relevant/outside of scope

Duplicate data
(n = 6)

FIGURE 1. Flow of studies.

with a high likelihood of bias, as assessed by the Risk of
Bias tool.11 Funnel plots were performed to assess for the
possibility of publication bias if there were suﬃcient trials
(> 10).11
Separate analyses were planned for the following
interventions based on the age of the participants and/or
attributes of the interventions: (1) breastfeeding (0 to 2 y);
(2) topical anesthetics (children 0-12 y, adolescents > 12 y
and adults); (3) sweet tasting solutions (0-2 y); and (4)
vapocoolants (children 0 to 3 y, children older than 3 to 17 y,
and adults). In addition, separate analyses were conducted
to account for diﬀerences in the timing of administration of
interventions (ie, breastfeeding immediately before, during,
and after the procedure vs. breastfeeding prevaccine injection). Finally, subgroup analyses were planned to examine
the impact of sucrose concentration according to 3 dose
intervals: low concentration (< 20%), moderate concentration (20% to <50%), and high concentration (Z50%).
Analyses are presented according to these decisions. Posthoc additional analyses were carried out to examine the
eﬀects of study methodology, heterogeneity, or both.

Evidence Profiles and Summary of Findings
The GRADE proﬁler software (version 3.6.1) was
used to create evidence proﬁles and summary of ﬁndings
tables in which all judgments and information pertaining to
the evaluation of the quality of evidence were recorded. The
quality of evidence could be rated as high, moderate, low,
and very low. If a beneﬁt was noted across all the critical
outcomes, the intervention was said to be beneﬁcial; if the
Copyright
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results were inconsistent, the intervention was said to have
mixed beneﬁt. Interventions without statistical evidence of
beneﬁt were said to have no evidence of beneﬁt.

RESULTS
The database searches yielded 114,251 references and
an additional 138 references were identiﬁed separately from
manual searches. All references were stored in an EndNote
library that identiﬁed 32,155 duplicates. The remaining
82,234 references were reviewed by 2 of the authors (V.S.,
A.T.) against the inclusion criteria.9 Five studies were
excluded after reviewing the full manuscript as it included:
(1) combined interventions versus control (n = 1)17; (2) a
no comparator group (n = 2),18,19; (3) did not include
intervention according to the clinical question (n = 1)20;
and (4) the procedure was SC injection of normal saline
(n = 1).21
Sixty-one studies investigating pharmacological and
combined interventions were included in the review.22–82 In
6 cases, multiple citations were identiﬁed for the same
study; 2 of these included a dissertation47,59 and published
manuscript with the same data,46,58 whereas the other 4
included multiple citations for the same study.28,31,32,63 A
total of 55 studies were included in this review. The study
selection log is shown in Figure 1.
Characteristics of included studies are described
in Table 2. Except for 2 studies39,82 that used cross-over
designs, the trials used between-groups (parallel) designs.
All studies provided data for Z2 treatment arms. The

2015 Wolters Kluwer Health, Inc. All rights reserved.
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TABLE 2. Characteristics of the Trials Included in the Systematic Review

First Author
Year, Country

Injection Details

Population Enrolled, Design,
Setting

Intervention

Should breastfeeding be used during vaccine injections in children 0-2 y?
Breastfeeding during and after
Abdel Razek
Vaccine NR; no injection details N = 120; infants 1-12 mo;
the procedure (n = 60)
2009,22
between-groups design;
Jordan
multicenter, maternal and child or
Control (no intervention and
health centers
restrained by the mother
during injection) (n = 60)
Dilli 2009 (1),23 Hepatitis B injections at 0-2 wk, 1 N = 250; infants and children 0- Infants <6 mo:
48 mo; between-groups design; Breastfeeding 30-60 s before and
Turkey
and 6 mo or MMR at 12 mo;
during the procedure (n = 73)
single center, hospital well
BCG 2 mo; DTP-IPV-Hib 2, 4,
or
child unit
6, and 16-24 mo; 16- or 25-mm
Control (no intervention)
needle; single or multiple
(n = 85)
injections; IM or SC or ID;
Infants and children 6-48 mow:
vastus lateralis or deltoid
Sucrose 12% 2 mL 2 min before
the procedure (n = 34)
or
Lidocaine-prilocaine cream 5%
1 g 1 h before the procedure;
applied on lateral region of
right thigh or deltoid (n = 24)
or
Control (no intervention)
(n = 30)
Efe 2007,24
DTaP 0.5 mL IM; 26-G, 15.9N = 66; infants 2-4 mo; between- Breastfeeding before, during, and
Turkey
mm needle; 90-degree angle;
groups design; single center,
after the procedure (n = 33)
anterior thigh
hospital healthy child clinic
or
Control (swaddled in the
bassinets during the procedure
and mother encouraged to
soothe the infant verbally)
(n = 33)
Goswami 2013 wDPT 0.5 mL IM; 23-G, 25.4Breastfeeding starting 2 min
N = 120; infants <3 mo;
(1)25 India
before and throughout the
mm needle; 90-degree angle;
between-groups design; single
procedure (n = 40)
anterolateral thigh
center, hospital immunization
or
clinic
Dextrose 25% 2 mL 2 min before
procedure (n = 40)w
or
Distilled water 2 mL 2 min before
procedure (n = 40)
Iqbal 2014,26
Breastfeeding 2 min before and
BCG 0.05 mL ID; 25-26 G short N = 150; full-term neonates
throughout the procedure
Pakistan
beveled needle; lower half of
<48 h; between-groups design;
(n = 75)
the right deltoid muscle
single center, nursery in a
or
hospital
Control (infant placed on a table
with mother next to the infant
and helping in holding and
soothing verbally) (n = 75)
Modarres
Breastfeeding 2 min before,
Hepatitis B 0.5 mL IM; 23-G, 1- N = 130; full-term neonates
2013,27 Iran
during, and after the procedure
inch needle; 90-degree angle;
<24 h; between-groups design
(n = 65)
anterior thigh
single center, nursery in a
(same as
or
hospital
Modarres
Control (held in the mother’s
2007)
arms) (n = 65)
Shah Ali 2009,29 DPT 0.5 mL IM; 23-G, 25-mm
N = 76; infants 2-4 mo; between- Breastfeeding starting 2 min
needle
groups design; multicenter,
before, during, and 15 s
Iran (same as
primary care practices
postinjection (n = 38)
Taavoni 2009,
or
2010 and
2010a)

Critical Outcomes*
Distress: NIPS, WongBaker FACES Pain
Rating Scale, Cry

Distress: NIPS, Cry

Distress: Cry

Distress: MFCS, Cry

Distress: DAN

Distress: DAN

Distress: MBPS

(Continued )
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TABLE 2. (continued)
First Author
Year, Country

Injection Details

Taavoni 2009,30 DPT 0.5 mL IM; 23-G, 25-mm
needle
Iran (same as
Taavoni 2010
and 2010a,
and Shah Ali
2009)
Thomas 2011,33 DPT IM; no injection details
India

Population Enrolled, Design,
Setting

Intervention

Mother holding infant starting
2 min before, during, and 15 s
postinjection (n = 38)
N = 76; infants 2-4 mo; between- Breastfeeding starting 2 min
groups design; multicenter,
before, during, and 15 s
primary care practices
postinjection (n = 38)
or
Control (infant supine) (n = 38)

Critical Outcomes*

Distress: MBPS

Distress: MNIPS
Breastfeeding 2 min before and
during procedure (n = 20)
or
Control (no intervention)
(n = 20)
If breastfeeding is not used during vaccine injections, should breastfeeding be used before vaccine injections in children 0-2 y?
Distress: APS,
Achema 2011
DPT IM; no injection details
N = 60; infants 6 wk; betweenBreast feeding 1 h before the
PAINAD
(1),34 Nigeria
groups design; multicenter,
procedure (n = 20)
primary health centers
or
Lidocaine-prilocaine cream
applied 1 h before the
procedure (n = 20)w
or
Control (mothers held and
cuddled their infant before the
procedure) (n = 20)
Sahebihagh
DPT, hepatitis B vaccine IM; no N = 120; infants <3 mo;
Breastfeeding based on infant’s Distress: NIPS, Cry
2011 (1),35
injection details
between-groups design;
appetite before the procedure
Iran
multicenter, health centers
(n = 30)
or
Sucrose 25% 2 min before the
procedure (0.6 mL/kg)
(n = 30)w
or
Breast feeding based on infant’s
appetite followed by sucrose
25% 2 min before the
procedure (0.6 mL/kg)
(n = 30)w
or
Control (no intervention)
(n = 30)
Should topical anesthetics be applied before vaccine injections in children 0-12 y?
Abuelkheir
Lidocaine-prilocaine cream 5% Distress: MBPS, VAS,
N = 216 children 2 mo to 6 y;
DTP, HAV, inﬂuenza, IPV,
2014,36 Saudi
Cry
0.5 g, application time range
between-groups design; single
MCV, measles, MMR, PCV13,
(19-103 min), (n = 107)
center, hospital paediatric
Arabia
pentavalent DTP-HBV-HIB,
or
clinic
tetravalent DTP-HIB, varicella
Placebo cream 0.5 g, application
IM or SC; lateral region of the
time range (32-97 min),
thigh in children <1 y; deltoid
(n = 109)
for children Z1 y
Achema 2011
Distress: APS,
DPT IM; no injection details
N = 60; infants 6 wk; betweenBreast feeding 1 h before the
(2),34 Nigeria
PAINAD
groups design; multicenter,
procedure (n = 20)w
primary health centers
or
Lidocaine-prilocaine cream 5%
(dose NR) applied 1 h before
the procedure (n = 20)
or
Control (mothers held and
cuddled their infant before the
procedure) (n = 20)
N = 40; infants 5-15 wk;
between-groups design; single
center, hospital clinic

(Continued )
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TABLE 2. (continued)
First Author
Year, Country
BasiriMoghadam
2014,37 Iran

Injection Details
DPT 0.5 mL IM; 23-G, 25-mm
needle; vastus lateralis

Population Enrolled, Design,
Setting
N = 50; infants 4 mo; betweengroups design; single center;
clinic

Cassidy 2001,38 DPTP 1 mL IM; 25-G, 15-mm
Canada
needle; 90-degree angle; middeltoid

N = 161; children 4-6 y; betweengroups design; multicenter,
urban and rural outpatient
clinics

Cohen 1999
(2),39 USA

Hepatitis B IM; no injection
details

N = 39; children 9-11 y; crossover design; single center,
school health clinic

Cohen 2006
(3,4),40 USA

Hib IM, MMR, and Varivax SC; N = 84; infants evaluated at 12
no injection details
and 18 mo; between-groups
longitudinal design; single
center, rural health clinic

Cohen Reis
1997 (1),41
USA

DTaP 0.5 mL IM; 26-G, ½-inch N = 62; children 4-6 y; betweenneedle; 90-degree angle; deltoid
groups design; single center,
hospital primary care center

Dilli 2009 (2),23 Hepatitis B injections at 0-2 wk, 1 N = 250; infants and children 048 mo; between-groups design;
Turkey
and 6 mo or MMR at 12 mo;
single center, hospital well
BCG 2 mo; DTP-IPV-Hib 2, 4,
child unit
6, and 16-24 mo; 16- or 25-mm
needle; single or multiple
injections; IM, SC, or ID
vastus lateralis or deltoid

Intervention
Lidocaine-prilocaine cream 5%
2 g 1 h before the procedure
(n = 16)
or
Rattle shaken 30 s before and 15 s
after the procedure (n = 16)w
or
Control (n = 18)
Lidocaine-prilocaine patch 5%
1 g 1-2 h and removed no more
than 10 min before the
procedure (n = 83)
or
Placebo patch 1 g 1-2 h and
removed no more than 10 min
before the procedure (n = 76)
Lidocaine-prilocaine cream 5% 2 g
1 h before the procedure (n = 34)
or
Nurse coaching and movie
distraction (n = 34)w
or
Control (standard care) (n = 34)
Distraction (nurses trained on
implementation of the
distraction protocol) (n = 28)w
or
Lidocaine-prilocaine cream 5%
2 g 1 h before the procedure
(n = 28)
or
Control (standard care provided
by nurses and included some
distraction) (n = 28)
Lidocaine-prilocaine cream 5% 2.5 g
for 60 min + distraction (blow on
a pinwheel held by themselves or
their parents) (n = 21)
or
Vapocoolant (Fluorimethane) spray
on a cotton ball applied for 15 s
immediately before the
procedure + distraction (n = 20)w
or
Distraction alone (n = 21)
Infants <6 mow:
Breastfeeding 30-60 s before and
during the procedure (n = 73)
or
Control (no intervention)
(n = 85)
Infants and children 6-48 mo:
Sucrose 12% 2 mL 2 min before
the procedure (n = 34)w
or
Lidocaine-prilocaine cream 5%
1 g 1 h before the procedure
(n = 24)
or
Control (no intervention)
(n = 30)

Critical Outcomes*
Distress: MBPS

Pain: FPS, VAS,
CFCS, CHEOPS

Pain: VAS,
CAMPIS-R

Distress: MBPS

Pain: Bieri FPS, VAS

Distress: NIPS, Cry
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TABLE 2. (continued)
First Author
Year, Country

Injection Details

Gupta 2013
(1),42 India

wDPT 0.5 mL IM; 23-G, 1-inch
needle; anterolateral thigh

Halperin
2000,43
Canada

MMR 0.5 mL SC; 25-G, 15-mm
needle; mid-thigh

Halperin
2002,44
Canada

Part A: DPTaP-IPV-Hib and
hepatitis B 0.5 mL, IM; 23-G,
25-mm needle
Part B: DPTaP-IPV-Hib 0.5 mL
at 2, 4, 6 mo and hepatitis B
0.5 mL IM at <2, 2, 6 mo; 25or 23-G (6 mo), 25-mm needle

Kumar (thesis
DPT-HiB-hepatitis IM; 25-G, 12014),45 India
inch needle; 90-degree angle;
anterolateral thigh

O’Brien 2004
(thesis
2004),46
Canada

MMR 0.5 mL SC; 25-G, 16-mm
needle; deltoid

Taddio 1994,48
Canada

DPT 0.5 mL IM; 25-G, 16-mm
needle; mid-thigh

Population Enrolled, Design,
Setting

Intervention

N = 90; infants <3 mo; between- Lidocaine-prilocaine cream 5%
groups design; single center,
1 g 1 h + breast feeding 2 min
immunization clinic
before the procedure (n = 30)w
or
Lidocaine-prilocaine cream 5%
1 g 1 h + 2 mL distilled water
2 min before the procedure
(n = 30)
or
Placebo cream 1 g 1 h + 2 mL
distilled water 2 min before the
procedure (n = 30)
N = 160; infants and children
Lidocaine-prilocaine patch 5%
Z1 y; between-groups design;
1 g 1-3 h before the procedure
single center, ambulatory clinic
(n = 80)
or
Placebo patch 1 g 1-3 h before the
procedure (n = 80)
Part A: Lidocaine-prilocaine
N = 165
patch 5% 1 g 1-3 h before the
Part A (N = 109); infants 6 mo
procedure (n = 54)
Part B (N = 56): infants 0-2 mo;
or
between-groups design;
multicenter, ambulatory clinics Placebo patch 1 g 1-3 h before the
procedure (n = 55)
Part B: Lidocaine-prilocaine
patch 5% 1 g 1-3 h before the
procedure (n = 28)
or
Placebo patch 1 g 1-3 h before the
procedure (n = 28)
N = 300; infants 6 wk to 6 mo;
Lidocaine-prilocaine cream 5%
between-groups design; single
1 g 1 h before the procedure
center, immunization clinic
(n = 75)
or
Lidocaine spray 10% sprayed at
the injection site 10 s before the
procedure (n = 75)w
or
Lidocaine spray
10% + vapocoolant
(benzocaine 0.36%, polyvinyl
polymer 2.52% in propellant
solvent) sprayed at the
injection site 10 s before the
procedure (n = 75)w
or
Control (topical spray of water at
41C) sprayed at the injection
site 10 s before the procedure
(n = 75)
N = 120; infants >12 mo;
Amethocaine gel 4% 1 g 30between-groups design;
45 min before the procedure
multicenter, outpatient clinics
(n = 61)
or
Placebo 1 g 30-45 min before the
procedure (n = 59)
N = 100; infants 4-6 mo;
Lidocaine-prilocaine cream 5%
between-groups design; single
2.5 g 1-2 h before the procedure
center, outpatient clinic
(n = 49)
or

Critical Outcomes*
Distress: MFCS, Cry

Distress: MBPS, Cry

Distress: MBPS

Distress: MBPS

Distress: MBPS,
NFCS, VAS, Cry

Distress: MBPS, VAS,
Cry
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TABLE 2. (continued)
First Author
Year, Country

Injection Details

Population Enrolled, Design,
Setting

Intervention

Critical Outcomes*

Placebo 2.5 g 1-2 h 1 h before the
procedure (n = 47)
Uhari 1993,49
DPT IM (98% of children, 2% N = 155; infants 3-28 mo;
Lidocaine-prilocaine cream 5% 1 h Distress: VAS
Finland
NR); no injection details
between-group design;
before the procedure (n = 79)
multicenter, outpatient clinics or
Placebo cream 1 h before the
procedure (n = 76)
Should topical anesthetics be applied before vaccine injections in adolescents >12 y and adults?
Hansen 1993,50 MMR SC; no injection details
N = 118; children 11-15 y;
Lidocaine-prilocaine cream 5% Distress: Likert scale
Denmark
between-groups design;
1 g 1 h before the procedure
multicenter, outpatient clinics
(n = 58)
or
Placebo (coconut oil cream) 1 g
1 h before the procedure
(n = 59)
Taddio 1992,51 Inﬂuenza virus vaccine (Fluzone) N = 60; adult volunteers;
Lidocaine-prilocaine cream 5% Pain: MBPS
Canada
0.5 mL IM; 22-G, 1-inch
between-groups design; single
2.5 g 1-2 h before the procedure
needle; arms
center, hospital setting
(n = 29)
or
Placebo 2.5 g 1-2 h before the
procedure (n = 31)
Should topical anesthetics be used before vaccine injections in combination with breastfeeding during vaccine injections (rather than topical anesthetics or
breastfeeding alone) in children 0-2 y?
Gupta 2013
wDPT 0.5 mL IM; 23-G, 1-inch N = 90; infants <3 mo; between- Lidocaine-prilocaine cream 5% Distress: MFCS, Cry
(2),42 India
needle; anterolateral thigh
groups design; single center,
1 g 1 h + breast feeding 2 min
immunization clinic
before the procedure (n = 30)
or
Lidocaine-prilocaine cream 5% 1 g
1 h + 2 mL distilled water 2 min
before the procedure (n = 30)w
or
Placebo cream 1 g 1 h + 2 mL
distilled water 2 min before the
procedure (n = 30)
Should sucrose solution be given before vaccine injections in children 0-2 y?
Allen 1996 (11 injection: hepatitis B 2 wk and N = 285; infant age categories: Sucrose 12% 2 mL administered Distress: Cry
12),52 USA
2 min before the procedure
2 wk (n = 50); 2 mo (n = 44);
9 mo; DTP 18 mo 2 injections:
4 mo (n = 50); 6 mo (n = 46); or
DTP and Hib 2 and 6 mo;
9 mo (n = 28); 15 mo (n = 30); Sterile water 2 mL administered
MMR and Hib 15 mo 3
2 min before the procedure
18 mo (n = 37); betweeninjections: DTP, Hib, hepatitis
or
groups design; single center,
B 4 mo; SC, thigh
Control (no intervention)
ambulatory clinic
n for each group NR
Barr 1995,53
Sucrose 50% 3 doses of 250 mL Distress: Cry
DTP, IM; thigh
N = 66; infants evaluated at 2
on tongue at 30-s intervals,
Canada
and 4 mo, between-groups
injection administered
design; longitudinal study
immediately after the last dose
single center, pediatric practice
(n = 30)
or
Sterile water 3 doses on the
tongue at 30-s intervals,
injection administered
immediately after the last dose
(n = 27)
Chattopadhyay DPT IM; anterolateral, midSucrose 2 mL administered over Distress: NIPS
N = 60; infants 6-11 mo;
2011,54 India
30 s, injection immediately
thigh
between-groups design; single
thereafter (n = 30)
center, hospital maternal and
or
child health clinic
Water 2 mL administered over
30 s, injection immediately
thereafter (n = 30)
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TABLE 2. (continued)
First Author
Year, Country

Injection Details

Population Enrolled, Design,
Setting

Dilli 2009 (3),23 Hepatitis B injections at 0-2 wk, 1 N = 250; infants and children 048 mo; between-groups design;
Turkey
and 6 mo or MMR at 12 mo;
single center, hospital well
BCG 2 mo; DTP-IPV-Hib 2, 4,
child unit
6, and 16-24 mo; 16- or 25-mm
needle; single or multiple
injections; IM, SC or ID;
vastus lateralis or deltoid

Intervention

Infants <6 mow:
Breastfeeding 30-60 s before and
during the procedure (n = 73)
or
Control (no intervention)
(n = 85)
Infants and children 6-48 mo:
Sucrose 12% 2 mL 2 min before
the procedure (n = 34)
or
Lidocaine-prilocaine cream
1 g 1 h before the procedure;
applied on lateral region of
right thigh or deltoid (n = 24)w
or
Control (no intervention)
(n = 30)
Harrington
N = 230; infants 2-4 mo;
Sucrose 24% 2 mL 2 min before
Hepatitis B, DTP-IPV-Hib,
2012 (3,4),55
between-groups design; single
the procedure + combined
PCV; 0.5 mL/vaccine IM; 23center, hospital clinic
physical intervention
USA
G, 1.59-cm needle; 90-degree
(swaddling, side/stomach
angle; anterolateral thigh;
position, shushing, swinging,
sequential injections
and sucking) (n = 58)
or
Sucrose 24% 2 mL 2 min before
the procedure + control (no
intervention) (n = 58)
or
Water 2 mL 2 min before the
procedure + combined
physical intervention (as
described above) (n = 58)
or
Water 2 mL 2 min before the
procedure + control (no
intervention) (n = 56)
Harrison 2014 Hib, MCV IM, MMR, SC at
Sucrose 33% in 0.5 mL aliquots
N = 29; infants 12 and 18 mo;
(1,2),56
2 min before ﬁrst injection and
12 mo; varicella SC at 18 mo;
between-groups design; single
then repeated 0.5 mL before
Australia
no injection details
center, hospital immunization
each injection (n = 15)
clinic
or
Water in 0.5 mL aliquots 2 min
before ﬁrst injection and then
repeated 0.5 mL before each
injection (n = 14)
Hatﬁeld 2008,57 DTaP-hepatitis B-IPV followed N = 100; infants 2 and 4 mo;
Sucrose 24% 0.6 mL/kg 2 min
before + NNS using a paciﬁer
between-groups design; single
USA
3 min later by Hib followed
2 min before, during, and 7 min
center, ambulatory pediatric
2 min later by pneumococcal
after the initial injection
clinic
conjugate vaccine, IM; 25-G,
(n = 38)
1-inch needle
or
Water 0.6 mL/kg 2 min
before + NNS using a paciﬁer
2 min before , during, and
7 min after the initial injection
(n = 45)
Hatﬁeld
Sucrose 24% 0.6 mL/kg 2 min
DTaP-hepatitis B-IPV, Hib, and N = 40; infants 2 and 4 mo;
2008a,58 USA
before + NNS using a paciﬁer
between-groups longitudinal
pneumococcal conjugate
2 min before, during, and 3 min
design; single center,
vaccine, IM; 25-G, 1-inch
postinjection (n = 20)
ambulatory pediatric clinic
needle
or

Critical Outcomes*
Distress: NIPS, Cry

Distress: Modiﬁed
Riley Pain Scale

Distress: FLACC, Cry

Distress: UWCH Pain
Scale

Distress: UWCH Pain
Scale
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TABLE 2. (continued)
First Author
Year, Country

Injection Details

Population Enrolled, Design,
Setting

Intervention

Water 0.6 mL/kg + NNS using a
paciﬁer 2 min before, during, and
3 min postinjection (n = 20)
Lewindon
Oral polio, DTP, Hib, IM; thigh N = 110; infants 7-38 wk;
Sucrose 75% 2 mL over 15 s
1998,60
between-groups design; single
followed by the procedure
Australia
center, ambulatory clinic
(n = 54)
or
Water 2 mL over 15 s followed by
the procedure (n = 53),
Liaw 2011 (2),61 Hepatitis B vaccine IM; 90N = 165; newborns after second- Non-nutritive sucking using
standard silicone newborn
China
degree angle; vastus lateralis;
third day of life; betweenpaciﬁer 2 min before the
aspiration before injection
groups design; single center,
procedure (n = 55)w
nursery in a hospital
or
Sucrose 20% 2 mL using a
syringe 2 min before the
procedure (n = 55)
or
Control (gentle touch and verbal
comfort) (n = 55)
Moradi 2012
Hepatitis B 0.5 mL, IM; no
N = 91; newborns 1-2 d of age; Sucrose 20% 2 mL 2 min before
(1,2),62 Iran
injection details
between-groups design; single
the procedure (n = 30)
center, hospital setting
or
(same as
Sucrose 50% 2 mL 2 min before
Moradi
the procedure (n = 30)
2012a)
or
Water 2 mL 2 min before the
procedure (n = 31)
Mowrey (thesis DTaP-IPV-Hib, hepatitis B,
N = 52; infants 2-6 mo; between- Sucrose 50% 2 mL 2 min before
2008),64 USA
prevnar injections, IM; no
groups design; single center,
the procedure (n = 25)
injection details
hospital pediatric clinic
or
Water 2 mL over 1 min (n = 24)
Poulsen 2009,65 DTaP-IPV + Hib, IM; grey
N = 67; infants 3-9 mo; single
Sucrose 12% 2 mL 2 min before
Denmark
needle 0.4 19
center, hospital
the procedure (n = NR)
or
Water 2 mL 2 min before the
procedure (n = NR)
Priambodo
2008,66
Indonesia

Critical Outcomes*

Distress: VAS, Cry

Distress: NFCS, Cry

Distress: NIPS

Distress: MBPS, Cry

Distress: NIPS (this
study was not
included in the
meta-analysis for
critical outcomes as
scores NR)
Distress: Cry

N = 86; infants 4-6 mo; between- Sucrose 75% 2 mL 2 min before
the procedure (n = 42)
groups design; multicenter,
hospital outpatient clinic and or
Water 2 mL 2 min before the
public health centers
procedure (n = 44)
Ramenghi 2002 DTP followed by Hib 3 min later, N = 184; infants 7-25 wk;
Sucrose 25% 2 mL 2 min before Distress: Cry
(1,2),67 UK
IM; thigh
between-groups design; single
the procedure (n = 46)
center, immunization clinic
or
Sucrose 50% 2 mL 2 min before
the procedure (n = 45)
or
Hydrogenated glucose 40% 2 mL
2 min before the procedure
(n = 46)w
or
Water 2 mL 2 min before the
procedure (n = 47)
Sahebihagh
DPT, hepatitis B vaccine IM; no N = 120 infants <3 mo;
Breast feeding based on infant’s Distress: NIPS, Cry
2011 (4),35
injection details
between-groups design;
appetite before the procedure
Iran
multicenter, health centers
(n = 30)w
or
Sucrose 25% 2 min before the
procedure (0.6 mL/kg) (n = 30)
wDPT, IM; anterolateral thigh
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TABLE 2. (continued)
First Author
Year, Country

Injection Details

Population Enrolled, Design,
Setting

Intervention

or
Breast feeding based on infant’s
appetite followed by sucrose
25% 2 min before the
procedure (0.6 mL/kg)
(n = 30)w
or
Control (no intervention)
(n = 30)
Soriano Faura Hepatitis B or DPT IM; no
N = 323; infants 1-6 mo;
Sucrose 75% 2 mL 1 min before
2003,68 Spain
injection details
between-groups design;
the procedure (n = 165)
multicenter, pediatric clinics
or
Water 2 mL 1 min before the
procedure (n = 158)
Yilmaz 2014
DTaP/HiB/IPV, pneumococcal N = 537; infants 16-19 mo;
Sucrose 75% 2 mL 2 min before
(1,2),69
and hepatitis A, IM; deltoid
between-groups design; single
the procedure (n = 179)
Turkey
center, hospital well child unit or
Sucrose 25% 2 mL 2 min before
the procedure (n = 179)
or
Water 2 mL 2 min before the
procedure (n = 179)
Should glucose solution be given before vaccine injections in children 0-2 y?
Chermont 2009 Hepatitis B 0.5 mL IM; 25-G
N = 640; newborn 12-72 h;
Mother holding diaper-clad
(4),70 Brazil
needle; anterolateral thigh
between-groups design; single
neonate on chest (skin-tocenter, hospital maternity ward
skin) + 1 mL water 2 min
before, during, and 2 min after
procedure (n = 160)w
or
Diaper-clad neonate in
crib + 1 mL water (n = 160)
or
Mother holding diaper-clad
neonate on chest (skin-toskin) + 1 mL dextrose 25%
solution 2 min before, during,
and 2 min after procedure
(n = 160)w
or
Diaper-clad neonate in
crib + 1 mL dextrose 25%
solution (n = 160)
Golestan 2007 Hepatitis B; no injection details N = 90; newborn <24 h
Glucose 50% 2 mL orally in
(1,2),71 Iran
between-groups design; single
<1 min followed by the
center, hospital maternity ward
procedure 2 min later (n = 30)
or
Water 2 mL orally in <1 min
followed by the procedure
2 min later (n = 30)
or
Control (no intervention)
(n = 30)
Goswami 2013 wDPT 0.5 mL IM; 23-G, 25.4Breastfeeding starting 2 min
N = 120; infants <3 mo;
(2),25 India
before and throughout the
mm needle; 90-degree angle;
between-groups design; single
procedure (n = 40)w
anterolateral thigh
center, hospital immunization
or
clinic
Dextrose 25% 2 mL 2 min before
procedure (n = 40)
or
Distilled water 2 mL 2 min before
procedure (n = 40)

Critical Outcomes*

Distress: Cry

Distress: Cry,
CHEOPS

Distress: NFCS,
NIPS, PIPP

Distress: Cry

Distress: MFCS, Cry
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TABLE 2. (continued)
First Author
Year, Country
Kassab 2012,72
Jordon

Injection Details

Population Enrolled, Design,
Setting

Intervention

Critical Outcomes*

N = 120; infants 2 mo; between- 25% glucose 2 mL immediately Distress: MBPS, Cry
groups design; multicenter,
before the procedure (n = 60)
child health care centers
or
Water 2 mL immediately before
the procedure (n = 60)
Distress: Cry
Mörelius 2009 DPT-IPV-HiB 0.5 mL IM;
N = 98; infants 3 mo; between- Water 1 mL using a syringe
(1,4),73
anterolateral thigh
groups design; single center,
followed by paciﬁer before the
Sweden
pediatric clinic
procedure (n = 25)
or
Water 1 mL using a syringe
before the procedure (n = 24)
or
Glucose 30% 1 mL using a
syringe followed by paciﬁer
before the procedure (n = 29)
or
Glucose 30% 1 mL using a
syringe before the procedure
(n = 20)
Thyr 2007,74
Distress: Cry
Infanrix, polio, Hib, IM; thigh
N = 110; infants evaluated at 3, 5 Glucose 30% 2 mL (0.6 g) 30 s
before, during, and 10-30 s
Sweden
and 12 mo; between-groups
after the procedure (n = 55)
design; longitudinal study;
single center, ambulatory clinic or
Sterile water 2 mL 30 s before,
during, and 10-30 s after the
procedure (n = 55)
Should sweet-tasting solutions (sucrose, glucose) be used before vaccine injections in combination with non-nutritive sucking (ﬁnger/thumb, paciﬁer)
during vaccine injections (rather than sweet-tasting solutions or non-nutritive sucking alone) in children 0-2 y?
Mörelius 2009 DPT-IPV-HiB 0.5 mL IM;
Distress: Cry
N = 98; infants 3 mo; between- Water 1 mL using a syringe
(3,4),73
anterolateral thigh
groups design; single center,
followed by paciﬁer (n = 25)
Sweden
pediatric clinic
or
Water 1 mL using a syringe
(n = 24)w
or
Glucose 30% 1 mL using a
syringe followed by paciﬁer
(n = 29)
or
Glucose 30% 1 mL using a
syringe (n = 20)
Should breastfeeding and sweet-tasting solutions (sucrose, glucose) be combined together before vaccine injections (rather than breastfeeding or sweettasting solutions alone) in children 0-2 y?
Sahebihagh
DPT, hepatitis B vaccine IM; no N = 120; infants <3 mo;
Breastfeeding based on infant’s Distress: NIPS, Cry
2011 (3,4),35
injection details
between-groups design;
appetite before the procedure
Iran
multicenter, health centers
(n = 30)
or
Sucrose 25% 2 min before the
procedure (0.6 mL/kg) (n = 30)
or
Breastfeeding based on infant’s
appetite followed by sucrose
25% 2 min before the
procedure (0.6 mL/kg) (n = 30)
or
Control (no intervention)
(n = 30)w
Should vapocoolants be applied before vaccine injections in children 0-3 y?
Maikler 1991
Distress: MAX , Cry
DPT 0.5 mL IM; 25-G, 5/8-inch N = 60; infants 6-30 wk; between- Refrigerant topical anesthetic
(1,2),75 USA
spray
needle; 90-degree angle;
groups design; multicenter,
(dicholortetraﬂuorethane) for
anterior thigh
pediatric ambulatory care and
2-3 s (n = 30)
private clinics
DTP/HIB/IPV, Hib, IM; 21-G,
15.9-mm needle; 90-degree
angle; anterolateral thigh
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TABLE 2. (continued)
First Author
Year, Country

Injection Details

Population Enrolled, Design,
Setting

Intervention

Critical Outcomes*

or
Control (compressed air spray)
for 2-3 s (n = 30)
Should vapocoolants be applied before vaccine injections in children >3-17 y?
Abbott 1995
DPT IM; no injection details
N = 90; children 4-5.5 y;
(1,2),76
between-groups design;
Canada
multicenter, health clinics

Refrigerant topical anesthetic
spray (Fluroethyl) on a sterile
cotton ball held for 10 s
(n = 30)
or
Placebo topical spray
(compressed air with Freon) on
a sterile cotton ball for 10 s
(n = 30)
or
Control (no treatment) (n = 30)
Cohen 2009,77 DPTaP, Measles-MumpsN = 57; children 4-6 y; between- Vapocoolant (ethyl chloride)
USA
Rubella, and IPV IM; 25-G, 1groups design; single center,
solution on a cotton ball
inch needle; thigh
primary pediatric care clinic
applied for B20 s (n = 31)
or
Control (standard care) (n = 26)
Cohen Reis
DTaP 0.5 mL IM; 26-G, ½-inch N = 62; children 4-6 y; between- Lidocaine-prilocaine cream 5%
1997 (1),41
needle; 90-degree angle; deltoid
groups design; single center,
2.5 g for 60 min + distraction
USA
hospital primary care center
(blow on a pinwheel held by
themselves or their parents)
(n = 21)w
or
Vapocoolant (Fluorimethane)
spray on a cotton ball applied
for 15 s immediately before the
procedure + distraction
(n = 20)
or
Distraction alone (n = 21)
Eland 1981
DPT 0.5 mL, IM; 25-G, 5/8-inch N = 40; children 4.7-5.7 y;
Refrigerant topical anesthetic
(3,4),78 USA
needle; vastus lateralis
between-groups design; single
spray (Frigiderm) + cognitive
center, pediatric clinic
information (n = 10)
or
Refrigerant topical anesthetic
spray (Frigiderm) + no
cognitive information (n = 10)
or
Aerosol air spray + cognitive
information (n = 10)
or
Aerosol air spray + no cognitive
information; spray applied 35 s on the leg before
vaccination (n = 10)
Luthy 2013
Vaccine NR; no injection details N = 68; children 2-12 y; between- Distraction (DVD before,
(1),79 USA
groups design; single center,
during, and after the
pediatric oﬃce
procedure) (n = 27)w
or
Vapocoolant spray for 3-7 s
before the procedure (n = 18)
or
Control (no intervention)
(n = 22)
Should vapocoolants be applied before vaccine injections in adults?
Mawhorter
Travel-speciﬁc vaccines IM or
N = 185; adults >18 y; between- Vapocoolant (Fluorimethane) on
2004,80 USA
SC; no injection details
groups design; single center,
a sterile cotton ball before the
travel clinic
procedure (n = 93)

Pain: VAS

Pain: FPS-R, VAS

Pain: Bieri FPS, VAS

Pain: VAS

VAS

Pain: McGill PPI
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TABLE 2. (continued)
First Author
Year, Country

Injection Details

Population Enrolled, Design,
Setting

Intervention

Critical Outcomes*

or
Placebo (41C, saline) on a sterile
cotton ball before the
procedure (n = 92)
Should acetaminophen be given before vaccine injections in individuals of all ages?
Pain: VAS
Hedén 2014,81 SC injection in implanted
N = 51; children 1-18 y; between- Lidocaine-prilocaine patch/cream
Sweden
intravenous port
groups design; single center,
5% Z60 min + paracetamol
pediatric oncology center
(40 mg/kg crushed tablet in 510 mL of jam or yogurt) 60 min
before procedure (n = 24)
or
Lidocaine-prilocaine patch/cream
5% Z60 min + placebo (40 mg/
kg crushed tablet in
5-10 mL of jam or yogurt) 60 min
before procedure (n = 27)
Should ibuprofen be given before vaccine injections in individuals of all ages?
Smith 1996,82
VC; 20-G needle
N = 10; healthy volunteers;
Ibuprofen 5% cream 2 g 60 min Pain: VAS
Australia
cross-over design; single center,
before the procedure (n = 10)
hospital setting
or
Lidocaine-prilocaine cream 5%
2 g 60 min before the procedure
(n = 10)
*Distress is the critical outcome in the absence of data for pain and/or fear in individuals incapable of self-report (eg, infants).
wData not included in the analysis for that particular clinical question.
Studies were identiﬁed using the following notation: “First Author” “Year of Publication,” “Country” [eg, Taddio 2014, Canada]. If studies contributed to
multiple analyses, then “(#)” was added to enable their discernment [eg, Taddio 2014 (1)]. If the same author published >1 study in the same year, then a lower
case letter was added after the ﬁrst article in the same year by the same author [eg, Taddio 2014a (1)].
Route: ID indicates intradermal; IM, intramuscular; SC, subcutaneous; VC, venous cannulation.
Outcomes: APS indicates Abbey Pain Scale; CAMPIS-R, Child-Adult Medical Procedure Interaction Scale-Revised; CFCS, Child Facial Coding System;
CHEOPS, Children’s Hospital of Eastern Ontario Pain Scale; Cry, cry duration; DAN, Douleur Aiguë du Nouveau-né; FLACC, Face, Legs, Arms, Crying,
Consolability; FPS, Faces Pain Scale; FPS-R, Faces Pain Scale-Revised; MAX, Maximally Discriminative Facial Movement Coding System; MBPS, Modiﬁed
Behavioral Pain Scale; McGill PPI, McGill Present Pain Intensity; MFCS, Modiﬁed Neonatal Facial Coding Score; MNIPS, Modiﬁed Neonatal Infant Pain
Scale; NFCS, Neonatal Facial Coding System; NIPS, Neonatal Infant Pain Scale; PAINAD, Pain Assessment in Advanced Dementia; PIPP, Premature Infant
Pain Proﬁle; UWCH Pain Scale, University of Wisconsin Children’s Pain Scale; VAS, Visual Analog Scale.
Vaccines: DPT indicates diphtheria, pertussis, tetanus; DPTP, diphtheria, pertussis, tetanus, polio; DTaP, diphtheria, tetanus, acellular pertussis; DTaPIPV-Hib, diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus inﬂuenzae type b; DTP, diphtheria, tetanus, pertussis; DTP-HBV-HIB,
diphtheria, tetanus, pertussis-hepatitis B vaccine-Haemophilus inﬂuenzae type b; DTP-HIB, diphtheria, tetanus, pertussis-Haemophilus inﬂuenzae type b; DTPHIB-IPV, diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, inactivated polio vaccine; DTP-IPV-Hib, diphtheria, tetanus toxoid, acellular pertussis,
inactivated polio vaccine, Haemophilus inﬂuenzae type b; HAV, hepatitis A vaccine; Hib, Haemophilus inﬂuenzae type b; IPV, inactivated polio vaccine; MCV,
meningococcal C vaccine; MMR, Measles-Mumps-Rubella; PCV13, pneumococcal conjugate vaccine 13; wDPT, whole cell DPT.
NR indicates not reported.

majority of the studies included children, adolescents, or
both (n = 52) and only 3 studies included adults.51,80,82

Quality of Included Studies and Risk of Bias
The methodologic quality (Risk of Bias) assessments for
the critical outcomes of the included studies are presented
in Table 3. Depending on the intervention evaluated, the
overall Risk of Bias varied from high (eg, for breastfeeding
and vapocoolants because of lack of blinding) to unclear (eg,
for topical anesthetics and sweet-tasting solutions as there
was insuﬃcient information to make judgments) to low Risk
of Bias (for acetaminophen based on a single study).

Overall Quality of Evidence and Treatment
Effects
A quantitative summary of the treatment eﬀects for
available critical outcomes are described below. For several
clinical questions, multiple indicators of the same critical outcome were included (eg, distress measured in the preprocedure
phase of the procedure, the acute phase, or the recovery phase,
or various combinations of these). For the purposes of
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presentation, the critical outcome indicators with the most
number of participants are included. If the critical outcome
was distress, the acute and the acute and recovery phases were
also prioritized over other indicators of distress for presentation. Further, a qualitative summary across all critical
outcomes is presented in Table 4. Information on immunogenicity (important outcome) is summarized in Table 5 while
information on other important outcomes (adverse events,
ﬁdelity, feasibility, and preference) is presented in Table 6.
Supporting GRADE Evidence Proﬁles and Summary of
Findings tables (Tables, Supplemental Digital Content 1 to 14)
and accompanying Forest plots (Figures, Supplemental Digital
Content 1 to 14) for critically important and important outcomes are included as Supplemental Digital Content.

Breastfeeding
Should Breastfeeding be Used During Vaccine
Injections in Children 0 to 2 Years?
The analgesic eﬀect of breastfeeding was examined in 9
trials22–27,29,30,33 including data on 858 infants (0 to 12 mo).
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TABLE 3. Assessment of Risk of Bias of Included Trials for Critical Outcomes

First Author

Adequate
Sequence
Generation

Blinding of
Allocation Participants and
Concealment
Personnel

Blinding of
Outcome
Assessment

Incomplete
Outcome Data
Addressed

Free of
Selective
Reporting

Free of
Other Overall
Bias
Risk

Should breastfeeding be used during vaccine injections in children 0-2 y?
Abdel Razek
No
No
No
Unclear
Yes
No
Yes
High
200922
Dilli 2009 (1)23
Unclear
Unclear
No
No
Yes
Yes
Yes
High
Efe 200724
Unclear
Unclear
No
Unclear
Yes
Yes
Unclear
High
Goswami 2013
Yes
Yes
No
No
Yes
Yes
Yes
High
(1)25
Iqbal 201426
Unclear
Unclear
No
Yes
Yes
Yes
Yes
High
Modarres 201327
Unclear
Unclear
No
No
Yes
Yes
Yes
High
Shah Ali 200929
No
No
No
No
Yes
Yes
Yes
High
Tavooni 200930
No
No
No
No
Yes
Yes
Yes
High
Thomas 201133
Unclear
Unclear
No
No
Yes
Yes
Unclear
High
If breastfeeding is not used during vaccine injections, should breastfeeding be used before vaccine injections in children 0-2 y?
Achema 2011
No
No
No
Unclear
Yes
Yes
Yes
High
(1)34
Sahebihagh 2011
Unclear
Unclear
Unclear
Yes
Yes
Unclear
Yes
Unclear
(1)35
Should topical anesthetics be applied before vaccine injections in children 0-12 y?
Abuelkeir 201436
Yes
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
Achema 2011
No
No
No
Unclear
Yes
Yes
Yes
High
(2)34
Basiri-Moghadam
No
Unclear
No
Yes
Yes
Yes
Yes
Unclear
201437
Cassidy 200138
Unclear
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
Cohen 1999 (2)39
Unclear
Unclear
No
No
No
Unclear
Yes
High
Cohen 2006
Unclear
Unclear
Unclear
No
Yes
Yes
Yes
High
(3,4)40
Cohen Reis 2007
Unclear
Unclear
No
No
Yes
Yes
Yes
High
(1)41
Dilli 2009 (2)23
Unclear
Unclear
Unclear
Yes
Yes
Unclear
Yes
Unclear
Gupta 2013 (1)42
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Low
Halperin 200043
Yes
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
Halperin 200244
Yes
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
Kumar 201445
Yes
No
Unclear
Unclear
Yes
Yes
Yes
High
O’Brien 2004
Yes
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
(thesis 2004)46
Taddio 199448
Unclear
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
Uhari 199349
Unclear
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
Should topical anesthetics be applied before vaccine injections in adolescents >12 y and adults?
Hansen 199350
Unclear
Unclear
Yes
Yes
Yes
Unclear
Unclear Unclear
Taddio 199251
Unclear
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
Should topical anesthetics be used before vaccine injections in combination with breastfeeding during vaccine injections (rather than topical anesthetics or
breastfeeding alone) in children 0-2 y?
Gupta 2013 (2)42
Yes
Yes
No
No
Yes
Yes
Yes
High
Should sucrose solution be given before vaccine injections in children 0-2 y?
Allen 1996 (1Unclear
Yes
Yes
Yes
Unclear
Yes
Yes
Unclear
12)52
Barr 199553
Unclear
Unclear
Unclear
Yes
Yes
Yes
Yes
Unclear
Chattopadhyay
Unclear
Unclear
Unclear
Unclear
Yes
Yes
Unclear Unclear
201154
Dilli 2009 (3)23
Unclear
Unclear
Unclear
Yes
Yes
Yes
Yes
Unclear
Harrington 2012
Unclear
Unclear
No
Yes
Yes
Yes
Yes
High
(3,4)55
Harrison 2014
Yes
Unclear
Unclear
Yes
Yes
Yes
Yes
Unclear
(1,2)56
Hatﬁeld 200857
Yes
Unclear
Unclear
Yes
Yes
Yes
Yes
Unclear
Hatﬁeld 2008a58
Yes
Unclear
Unclear
Yes
Yes
Yes
Yes
Unclear
Lewindon 199860
Unclear
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
Liaw 2011 (2)61
Yes
Unclear
Unclear
Yes
Yes
Yes
Yes
Unclear

(Continued )
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TABLE 3. (continued)

First Author

Adequate
Sequence
Generation

Blinding of
Allocation Participants and
Concealment
Personnel

Blinding of
Outcome
Assessment

Incomplete
Outcome Data
Addressed

Free of
Selective
Reporting

Free of
Other Overall
Bias
Risk

Moradi 2012
Unclear
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
(1,2)62
Mowrey 200864
Yes
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
Poulsen 200965
Unclear
Unclear
Yes
Yes
Yes
No
Unclear
High
Priambodo 200866
Yes
Unclear
Unclear
Unclear
Yes
Yes
Yes
Unclear
Ramenghi 2002
Yes
Yes
Unclear
Yes
Yes
Yes
Yes
Unclear
(1,2)67
Sahebihagh 2011
Unclear
Unclear
Unclear
Yes
Yes
Unclear
Yes
Unclear
(4)35
Soraino Faura
Unclear
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
200368
Yilmaz 2014
Unclear
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
(1,2)69
Should glucose solution be given before vaccine injections in children 0-2 y?
Chermont 2009
Unclear
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
(4)70
Golestan 2007
Unclear
Unclear
Unclear
Yes
Yes
Yes
Yes
Unclear
(1,2)71
Goswami 2013
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Low
(2)25
Kassab 201272
Yes
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
Mörelius 2009
Unclear
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
(1,4)73
Thyr 200774
Unclear
Unclear
No
Yes
Yes
Yes
Unclear
High
Should sweet-tasting solutions (sucrose, glucose) be used before vaccine injections in combination with non-nutritive sucking (ﬁnger/thumb, paciﬁer)
during vaccine injections (rather than sweet-tasting solutions or non-nutritive sucking alone) in children 0-2 y?
Mörelius 2009
Unclear
Unclear
No
No
Yes
Yes
Yes
High
(3,4)73
Should breastfeeding and sweet-tasting solutions (sucrose, glucose) be combined together before vaccine injections (rather than breastfeeding or sweettasting solutions alone) in children 0-2 y?
Sahebihagh 2011
Unclear
Unclear
Unclear
Yes
Yes
Unclear
Yes
Unclear
(3,4)35
Should vapocoolants be applied before vaccine injections in children 0-3 y?
Maikler 1991
Yes
Unclear
No
Yes
Yes
Yes
Unclear
High
(1,2)75
Should vapocoolants be applied before vaccine injections in children >3-17 y?
Abbott 1995
Unclear
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear
(1,2)76
Cohen 200977
Unclear
No
No
No
Yes
Yes
Yes
High
Cohen Reis 2007
Unclear
Unclear
No
No
Yes
Yes
Yes
High
(1)41
Eland 1981 (3,4)78
Unclear
Unclear
No
No
Yes
Yes
Unclear
High
Luthy 2013 (1)79
Yes
Unclear
No
No
Yes
Yes
Unclear
High
Should vapocoolants be applied before vaccine injections in adults?
Mawhorter
Yes
Unclear
No
Yes
Yes
No
Unclear
High
200480
Should acetaminophen be given before vaccine injections in individuals of all ages?
Hedén 201481
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Low
Should ibuprofen be given before vaccine injections in individuals of all ages?
Smith 199682
Unclear
Yes
Yes
Yes
Yes
Yes
Unclear Unclear
Studies were identiﬁed using the following notation: “First Author” “Year of Publication” [eg, Taddio 2014]. If studies contributed to multiple analyses,
then “(#)” was added to enable their discernment [eg, Taddio 2014 (1)]. If the same author published >1 study in the same year, then a lower case letter was
added after the ﬁrst article in the same year by the same author [eg, Taddio 2014a (1)].

In all studies, breastfeeding was commenced immediately
before vaccination and continued during and afterward. In
the included trials, the comparator arm varied from the
infant being swaddled in the bassinet/placed on the table24,26
held in the mother’s arms,27,29 restrained by the mother,22
given distilled water25 to a no intervention roup.23,30,33
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Beneﬁt of breastfeeding was observed for all the critical outcomes analyzed, including acute and acute plus
recovery distress (Table and Figure, Supplemental Digital
Content 1, http://links.lww.com/CJP/A249). The SMD was
1.78 (CI,  2.35,  1.22) for acute distress (n = 792; data
from 8 studies).22,23,25–27,29,30,33 For distress during the
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TABLE 4. Summary of Results for Critically Important Outcomes

Clinical Questions
Pharmacological interventions
Should breastfeeding be used during vaccine injections in
children 0-2 y?
If breastfeeding is not used during vaccine injections, should
breastfeeding be used before vaccine injections in children
0-2 y?
Should topical anesthetics be applied before vaccine
injections in children 0-12 y?
Should topical anesthetics be applied before vaccine
injections in adolescents >12 y and adults?
Should topical anesthetics be used before vaccine injections in
combination with breastfeeding during vaccine injections
(rather than topical anesthetics or breastfeeding alone) in
children 0-2 y?
Should sucrose solution be given before vaccine injections in
children 0-2 y?
Should glucose solution be given before vaccine injections in
children 0-2 y?
Should sweet-tasting solutions (sucrose, glucose) be used
before vaccine injections in combination with non-nutritive
sucking (ﬁnger/thumb, paciﬁer) during vaccine injections
(rather than sweet-tasting solutions or non-nutritive
sucking alone) in children 0-2 y?
Should breastfeeding and sweet-tasting solutions (sucrose,
glucose) be combined together before vaccine injections
(rather than breastfeeding or sweet-tasting solutions alone)
in children 0-2 y?
Should vapocoolants be applied before vaccine injections in
children 0-3 y?
Should vapocoolants be applied before vaccine injections in
children >3-17 y?
Should vapocoolants be applied before vaccine injections in
adults?
Should acetaminophen be given before vaccine injections in
individuals of all ages?
Should ibuprofen be given before vaccine injections in
individuals of all ages?

Critical Outcomes*

Beneﬁt of Interventionw

Quality of Evidencez

Distress

Yes

Very low

Distress

Mixed

Low

Pain, distress, fear

Mixed

Very low

Pain

Yes

Moderate

Distress

Mixed

Low

Distress

Yes

Moderate

Distress

Mixed

Moderate

Distress

Mixed

Very low

Distress

No

Low

Distress

No

Low

Pain

No

Low

Pain

Mixed

Low

Pain, distress

No

Low

Pain, distress

No

Very low

*Includes results for the critical outcomes that were evaluated in included studies only.
wThe results for the eﬀect of the intervention have been summarized across all evaluated critical outcomes, and are expressed using the following notation:
Yes = beneﬁt was observed across all evaluated critical outcomes; Mixed = beneﬁt was observed for Z1 but not all evaluated critical outcomes; No = no
evidence of beneﬁt was observed for any of the evaluated critical outcomes.
zReﬂects the lowest quality of evidence rating across all evaluated critical outcomes, whereby rankings range from High to Moderate to Low to Very low.
Distress is the critical outcome in the absence of data for pain and/or, fear, or both in individuals who cannot verbalize (eg, infants).

acute plus recovery phase (n = 424) the SMD was 1.89
(CI,  3.19,  0.59). Considerable heterogeneity was
reported for this outcome, which can be explained by
the potential diﬀerences in the implementation of the
intervention (breastfeeding and the control group) and age
of the infant (studies included infants less than 24 h of age
to up to 12 mo). There was low to very low quality of evidence due to methodologic limitations of the included
studies (Table, Supplemental Digital Content 2, http://
links.lww.com/CJP/A250).

or no intervention.35 The results were mixed (Table and
Figure, Supplemental Digital Content 3, http://links.lww.com/
CJP/A251). Breastfeeding prevaccine injection was associated
with lower acute distress: SMD  1.43 (CI, 2.14,  0.72) as
well as acute plus recovery distress combined: SMD 1.47 (CI,
2.05, 0.90) (Figure, Supplemental Digital Content 4,
http://links.lww.com/CJP/A252). No beneﬁt was noted for
distress recovery. The quality of evidence ranged from moderate to low quality (Table, Supplemental Digital Content 5,
http://links.lww.com/CJP/A253).

If Breastfeeding is Not Used During Vaccine
Injections, Should Breastfeeding be Used Before
Vaccine Injections in Children 0 to 2 Years?

Topical Anesthetics
Should Topical Anesthetics be Applied Before Vaccine
Injections in Children 0 to 12 Years?

Two trials34,35 including 100 infants (6 wk to less than
3 mo of age) evaluated the eﬀect of breastfeeding before
vaccination. Breastfeeding ceased 2 to 60 minutes
before injection.34,35 The control group included holding34
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Fifteen studies23,34,36–46,48,49 including infants and
children investigated the eﬀect of topical anesthetics. In 10
included studies, vaccines were administered intramuscularly34,37–39,41,42,44,45,48,49; in 2 studies,43,46 they were
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TABLE 5. Impact of Topical Anesthetics and Acetaminophen on Immune Response to Vaccines*

Lidocaine-Prilocaine 5% Patch43,44

Vaccinesw

Amethocaine Gel 4%46

Acetaminophen84–88

Seroconversion
Rate

GMCs of
Antibody
Titer

Seroconversion
Rate

GMCs of
Antibody
Titer

Seroconversion
Rate

GMCs of
Antibody
Titer

No eﬀect
No eﬀect
No eﬀect
No eﬀect
No eﬀect
No eﬀect
NA
NA

No eﬀect
No eﬀect
No eﬀect
No eﬀect
No eﬀect
No eﬀect
NA
NA

NAz
NA
NA
NA
NA
NA
NA
NA

NA
NA
NA
NA
NA
NA
NA
NA

NA
NA
NA
No eﬀect
NA
No eﬀect
No eﬀect
No eﬀect

Reduced
Reduced
Reduced
No eﬀect
Reduced
Reduced
No eﬀect
No eﬀect

No eﬀect
No eﬀect
No eﬀect
NA

No eﬀect
No eﬀect
No eﬀect
NA

No eﬀect
No eﬀect
No eﬀect
NA

No eﬀect
No eﬀect
No eﬀect
NA

NA
NA
NA
NA

NA
NA
NA
Reduced

DPTaP-IPV-Hib
Diphtheria
Tetanus
Pertussis
Polio virus (1, 2, and 3)
Haemophilus inﬂuenzae type b
Hepatitis B
Human rotavirus
Inﬂuenza
Mumps-Measles-Rubella
Mumps
Measles
Rubella
PHiD-CV

*Data on adverse events for topical anesthetics and oral analgesics are reported in Table 6.
wDPTaP-IPV-Hib = Diphtheria-Tetanus-acellular Pertussis-inactivated Poliovirus-Hemophilus inﬂuenzae type b; DTPa + HBV + IPV/Hib = Diphtheriateatnus-3 component acellular pertussis-hepatitis B-inactivated poliovirus type 1, 2 and 3-Hemophilus inﬂuenzae type; GMCs = Geometric mean concentrations; HRV = Human rotavirus vaccine; PHiD-CV = Pneumococcal nontypeable Haemophilus inﬂuenzae protein D-conjugate vaccine; MMR = MeaslesMumps-Rubella
zNA: no data available; No eﬀect = rate of seroconversion similar in topical anesthetic and placebo group; Reduced = reduction in the GMCs antibody
titers.

administered subcutaneously; and in 3 studies,23,36,40 both
intramuscular (IM) and SC vaccines were given. Lidocaineprilocaine cream 5% was applied in 11 studies,23,34,36,37,39–42,44,47,48 lidocaine-prilocaine patch 5% was
applied in 3 studies,38,43,44 whereas amethocaine gel 4% was
applied in 1 study.46 The majority of studies (n = 8)
included a placebo.36,38,41–43,45,47,48 A meta-analysis of 13
studies23,34,36–39,42–46,48,49 including 1424 infants demonstrated lower levels of acute distress in the topical anesthetics group: SMD 0.91 (CI, 1.36, 0.47). Observerrated acute distress for child was lower in the topical
anesthetics group: SMD  1.13 (CI, 1.78, 0.47) in 1
study including 42 children.41 For distress during the acute
plus recovery phase (n = 546) the SMD was 0.68 (CI,
1.24, 0.13). The results were mixed for other indicators
of distress. A meta-analysis of 3 studies38,39,41 including 269
children between 4 and 11 years showed no beneﬁt of
topical anesthetics on self-report of pain: SMD  0.29 (CI,
0.64, 0.05). However, removal of the data from 1 study
with a high Risk of Bias39 altered the result in favor of
topical anesthetics: SMD 0.47 (CI, 0.73, 0.21). The
SMD (CI) for fear was 0.04 (CI,  0.29, 0.37; n = 68)
(Table and Figure, Supplemental Digital Content 6, http://
links.lww.com/CJP/A254). The quality of evidence ranged
from moderate to very low (Table, Supplemental Digital
Content 7, http://links.lww.com/CJP/A255).

Should Topical Anesthetics be Applied Before Vaccine
Injections in Adolescents Older than 12 Years and
Adults?

Two studies50,51 evaluated the analgesic eﬀects of
topical anesthetics in adolescents older than 12 years and
adults. Pain was lower in the topical anesthetic group:
SMD 0.85 (CI, 1.38, 0.32) in the study by Taddio
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et al,51 whereas acute distress was not lower: SMD 0.05 (CI,
0.31, 0.41) in the study by Hansen et al50 (Table and
Figure, Supplemental Digital Content 8, http://links.lww.com/CJP/A256). The quality of evidence was moderate (Table, Supplemental Digital Content 9, http://links.lww.com/CJP/A257).

Immunogenicity
Three trials,43,44,46 including 445 infants and children
assessed antibody response following vaccination. Results
are presented in Table 5. There was no diﬀerence in the
immune response to vaccine in topical anesthetics compared with placebo group for Measles-Mumps-Rubella,
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus inﬂuenzae type b, and hepatitis B. In a
separate study, Dohlwitz et al83 reported no eﬀect of topical
anesthetics on Bacillus-Calmette-Guérin vaccine response
in 388 children.

Should Topical Anesthetics be Used Before Vaccine
Injections in Combination With Breastfeeding During
Vaccine Injections (Rather than Topical Anesthetics or
Breastfeeding Alone) in Children 0 to 2 Years?

In one study42 including 60 infants less than 3 months
of age, topical anesthetics combined with breastfeeding
were compared with topical anesthetics alone during vaccine injections. Distress was the critical outcome. The
results were mixed (Table and Figure, Supplemental Digital
Content 10, http://links.lww.com/CJP/A258). The combination of topical anesthetics preinjection and breastfeeding
during injection did not reduce distress in the acute phase of
the procedure (SMD:  0.35 [CI, 0.86, 0.16]); however,
distress during the acute plus recovery phase of the procedure was reduced (SMD: 0.83 [CI, 1.36, 0.30])
(Figure, Supplemental Digital Content 11, http://
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TABLE 6. Summary of the Impact of Interventions on Adverse Events,* Fidelity, Feasibility, and Willingness to Use and Pay

Outcomes
Interventions

Adverse Eventsw

Fidelity/Correct
Use of Intervention

Feasibility

Infant acceptance to
Incidence of aspiration,
NA
breastfeed23: 95%
vomiting, cyanosis, and
respiratory change22,24:
(n = 77)
Breastfeeding group: 0%
(n = 93)
Control group: 0% (n = 93)
Parent correct
Topical
Pallor36,38,43,44,46,51:
Feasibility for inclusion in
application38,48:
anesthetics
Topical anesthetic group: 42%
parent schedule48: 88%
(n = 442)
96% (n = 261)
(n = 96)
Placebo group: 18% (n = 439)
Ease of application for
Erythema36,38,43,44,46,51:
parent48: 91% (n = 96)
Topical anesthetic group: 29%
(n = 442)
Placebo group: 20% (n = 439)
NA
NA
Sweet-tasting
Cough, gagging, or choking
solutions
episodes58,60,64:
(sucrose)
Sucrose group: 3.4% (n = 119)
Water group: 0.8%
NA
NA
Sweet-tasting
Nausea, vomiting, or
solutions
physiological instability70:
(glucose)
Glucose group: 0% (n = 160)
Control group: 0% (n = 160)
Vapocoolants
Sting at the application
NA
NA
site41,79,80:
Vapocoolant group: 0.7%
(n = 142) (child had eczema)
Control group: 0% (n = 92)
NA
NA
Oral analgesics
Nausea81:
(acetaminophen) Acetaminophen group: 0%
(n = 24)
Placebo group: 2% (n = 27)
Breastfeeding

Willingness to Use and/or Pay
NA

Children willingness to use39: 33%
(n = 34)
Families/parents willingness to use49,50:
65% (n = 272)
Parents willing to pay $11.90 cents for
lidocaine-prilocaine cream for future
injections (n = 41)41
Parents willingness to use intervention56:
93% (n = 29) (sucrose or water)

NA

Parents would use vapocoolants in
future41,79: 82% (n = 38)
Parents willingness to pay: $8.40 (n = 41)41

NA

*Data on immunogenicity for topical anesthetics and oral analgesics are presented in Table 5.
wReported as percentages; n = number of participants contributing to the data.
NA indicates not applicable.

links.lww.com/CJP/A259). The quality of evidence was low
(Table, Supplemental Digital Content 12, http://links.lww.com/CJP/A260).

Sweet-tasting Solutions
Should Sucrose Solution be Given Before Vaccine
Injections in Children 0 to 2 Years?
Eighteen studies including infants and young children aged
2 weeks to 48 months investigated the eﬀects of
sucrose.23,35,52–58,60–62,64–69 The concentration of sucrose ranged
from 12% to 75% except for the study by Chattopadhyay
et al54 where the concentration of sucrose was described as a
“saturated solution.” The majority of studies (n = 9) used
sucrose in the concentration of 20% to 33%.35,55–58,61,62,67,69
Except for 3 studies,52,57,58 all used a volume of 2 mL. The
majority of studies (n = 15) administered sucrose 2 minutes
before the procedure.23,35,52,53,55–58,61,62,64–67,69
In a meta-analysis including 881 infants, sucrose was
associated with lower acute distress: SMD 0.37 (CI,  0.67,
0.06). Similarly, acute plus recovery distress score was
lower in the sucrose group: SMD  0.76 (CI, 1.19, 0.34);
n = 2071 (Table and Figure, Supplemental Digital Content
Copyright
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13, http://links.lww.com/CJP/A261). The RR (CI) for
dichotomous outcome of acute distress was 0.37 (CI, 0.20.69) (Figure, Supplemental Digital Content 14, http://links.lww.com/CJP/A262). The quality of evidence of included
studies was high to moderate (Table, Supplemental Digital
Content 15, http://links.lww.com/CJP/A263).

Subgroup Analysis
Beneﬁt of sucrose in the concentration of 50% or 70%
was observed for all the critical outcomes analyzed, including
acute distress and acute plus recovery distress. The SMD (CI)
were 0.31 ( 0.61, 0.02; n = 259 infants) for acute distress; and 1.43 ( 2.34, 0.52; n = 1006 infants) for acute
plus recovery distress. Mixed results were found for sucrose
in the concentration of 20% to 33%. Beneﬁt was observed
for the acute plus recovery (SMD 0.85 [CI, 1.6, 0.11])
and recovery phases (SMD  1.13 [CI:  1.89, 0.37]). There
was no evidence of a beneﬁt of sucrose in the concentration of
12% across all indicators of distress analyzed (Table and
Figure, Supplemental Digital Content 13, http://links.lww.com/CJP/A261).

2015 Wolters Kluwer Health, Inc. All rights reserved.
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Should Glucose Solution be Given Before Vaccine
Injections in Children 0 to 2 Years?

Six trials25,70–74 investigated the eﬀect of glucose on
vaccine injection pain in infants 12 hours to 12 months. The
concentration of glucose was 25% in 3 studies,25,70,72 30%
in 2 studies,73,74 and 50% in 1 study.71 The volume
administered ranged from 1 to 2 mL and timing varied from
2 minutes before to immediately prior the procedure. The
results were mixed (Table and Figure, Supplemental Digital
Content 16, http://links.lww.com/CJP/A264). In a metaanalysis including all trials (n = 818 infants), acute plus
recovery distress was lower in the glucose group: SMD
0.69 (CI, 1.03, 0.35). There was no evidence of a
beneﬁt of glucose on acute distress (n = 520): SMD 0.59
(CI, 1.38, 0.20) (Table and Figure, Supplemental Digital
Content 16, http://links.lww.com/CJP/A264). The quality
of evidence ranged from high to moderate (Table, Supplemental Digital Content 17, http://links.lww.com/CJP/
A265).

Should Sweet-tasting Solutions (Sucrose, Glucose) be
Used Before Vaccine Injections in Combination With
Non-Nutritive Sucking (Finger/Thumb, Paciﬁer)
During Vaccine Injections (Rather than Sweet-tasting
Solutions or Non-Nutritive Sucking Alone) in Children
0 to 2 Years?

One study73 including 74 infants 3 months of age
compared the eﬀect of sweet-tasting solutions (glucose)
before vaccine injection and non-nutritive sucking during
vaccine injection to sweet-tasting solution or non-nutritive
sucking alone. There was no evidence of beneﬁt of the
combination of glucose and non-nutritive sucking (paciﬁer)
compared with glucose or non-nutritive sucking (paciﬁer)
alone across all indicators of distress evaluated. For acute
plus recovery, the SMD was 0.32 (CI,  0.79, 0.15) and
the RR was 0.99 (CI, 0.78, 1.26) (Table and Figure, Supplemental Digital Content 18, http://links.lww.com/CJP/
A266). The included study did not assess treatment ﬁdelity
with non-nutritive sucking. The quality of evidence was
very low (Table, Supplemental Digital Content 19, http://
links.lww.com/CJP/A267).

Should Breastfeeding and Sweet-tasting Solutions
(Sucrose, Glucose) be Combined Together Before
Vaccine Injections (Rather than Breastfeeding or
Sweet-tasting Solutions Alone) in Children 0 to 2
Years?

One study35 including 90 infants aged less than 3
months evaluated the eﬀect of a combination of breastfeeding and sweet-tasting solutions (sucrose) versus
breastfeeding or sucrose alone. There was no evidence of a
beneﬁt of breastfeeding and sucrose versus either alone
across all indicators of distress, The SMD for acute distress
was 0.28 (CI, 0.34, 0.90) and for acute recovery it was
0.06 (CI, 0.37, 0.5) (Table and Figure, Supplemental
Digital Content 20, http://links.lww.com/CJP/A268). The
quality of evidence was low (Table, Supplemental Digital
Content 21, http://links.lww.com/CJP/A269).

Vapocoolants
Should Vapocoolants be Applied Before Vaccine
Injections in Children 0 to 3 Years?

One study75 including 60 infants between 6 weeks and
3 months investigated the eﬀect of vapocoolant versus
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control (compressed air spray). In this study, the vapocoolant and placebo were both sprayed on the injection site
for 2 to 3 seconds right before injection. Vapocoolant spray
did not reduce acute distress (the only indicator of distress
included in the study): SMD 0.44 (CI,  0.96, 0.07)
(Table and Figure, Supplemental Digital Content 22,
http://links.lww.com/CJP/A270). The quality of evidence
was low (Table, Supplemental Digital Content 23, http://
links.lww.com/CJP/A271).

Should Vapocoolants be Applied Before Vaccine
Injections in Children Older than 3 to 17 Years?
Five trials were included in the systematic
review.41,76–79 In 3 trials,41,76,77 the vapocoolant was
applied to the injection site using sterile cotton ball for 10 to
20 seconds, whereas in the other 2 trials, the vapocoolant
was sprayed directly on the site with application time of 3 to
7 seconds.78,79 The control group consisted of placebo
spray, distraction, or a no intervention group. In a metaanalysis of 4 trials including 228 children, there was no
evidence of a beneﬁt on pain: SMD 0.38 (CI, 0.89,
0.13) (Table and Figure, Supplemental Digital Content 24,
http://links.lww.com/CJP/A272). The quality of evidence
was low (Table, Supplemental Digital Content 25, http://
links.lww.com/CJP/A273).

Should Vapocoolants be Applied Before Vaccine
Injections in Adults?

One trial80 including 185 adults was identiﬁed for
inclusion in the review. A cotton ball saturated with
vapocoolant or cold saline (41C) was applied for 15 seconds
in the arm. Acute pain was lower in the vapocoolant group:
SMD 0.78 (CI,  1.08, 0.48) (Table and Figure, Supplemental Digital Content 26, http://links.lww.com/CJP/
A274). The quality of evidence was low (Table, Supplemental Digital Content 27, http://links.lww.com/CJP/
A275).

Oral Analgesics
Should (Oral) Acetaminophen be Given Before Vaccine
Injections in Individuals of all Ages?
No trial evaluating the eﬀectiveness of orally administered acetaminophen for vaccine injection pain was
identiﬁed, and indirect evidence was obtained from the
closest related needle procedure (SC injection into an
implanted intravenous port).81 The study population
included 51 infants and children (1 to 18 y of age) with
cancer randomized to acetaminophen or placebo
60 minutes before the procedure. All children in both the
groups also received lidocaine-prilocaine patch/cream.
There was no diﬀerence in pain between groups: SMD
0.64 (CI, 1.43, 0.15) (Table and Figure, Supplemental
Digital Content 28, http://links.lww.com/CJP/A276). The
quality of evidence was low (Table, Supplemental Digital
Content 29, http://links.lww.com/CJP/A277).

Immunogenicity
Five studies84–88 evaluated the eﬀect of prophylactic
acetaminophen/paracetamol (administered at the time or
just after the vaccine) on immune response to vaccination.
Results from these studies are presented in Table 5. In 3
trials including 442 adults, the use of prophylactic
acetaminophen did not aﬀect the immune response to
inﬂuenza vaccine as measured using the hemagglutination
inhibition antibody assay.84,85,87
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In the study by Doedée et al,86 use of prophylactic
paracetamol was associated with a 26% reduction in antihepatitis B surface antigen antibody levels in 178 adults
even though all participants achieved levels of >10.0 IU/L
(considered to be seroprotective). Prophylactic paracetamol
was associated with reduction in immune response to
DTPa + HBV + IPV/Hib (hexavalent diphtheria-tetanus-3
component acellular pertussis-hepatitis B-inactivated
poliovirus type 1, 2, and 3-Haemophilus inﬂuenzae type b);
and PHiD-CV (10-valent pneumococcal nontypeable Haemophilus inﬂuenzae protein D-conjugate vaccine) in 459
children.88

Should (Oral) Ibuprofen be Given Before Vaccine
Injections in Individuals of all Ages?
No trial was identiﬁed that evaluated orally administered ibuprofen for vaccine injection pain, and evidence was
obtained from a cross-over trial that compared the eﬀectiveness of ibuprofen 5% cream to lidocaine-prilocaine 5%
cream in 20 adults undergoing venipuncture.82 Lidocaineprilocaine 5% cream was superior to ibuprofen cream in
preventing the pain associated with venipuncture: SMD
0.77 (CI, 0.06, 1.48) (Table and Figure, Supplemental
Digital Content 30, http://links.lww.com/CJP/A278). The
quality of evidence was very low (Table, Supplemental
Digital Content 31, http://links.lww.com/CJP/A279).

Immunogenicity
No studies have evaluated the eﬀect of oral ibuprofen
on immune response to vaccines.

DISCUSSION
In this systematic review and meta-analysis, we
examined the eﬀectiveness of various pharmacological
interventions and combined interventions for vaccine
injection pain in individuals across the lifespan. These
interventions included breastfeeding during and before
vaccine injection, topical anesthetics, sweet-tasting solutions (sucrose and glucose), vapocoolants, oral analgesics
(acetaminophen and ibuprofen), and the combination of 2
interventions versus 1 intervention. We found evidence for
a beneﬁt of breastfeeding, topical anesthetics, sweet-tasting
solutions, and combinations of topical anesthetics and
breastfeeding for reducing vaccine injection pain in infants
and children. In adults, limited data demonstrate some
beneﬁt of topical anesthetics and vapocoolants.

Breastfeeding
This review found evidence of a beneﬁt of breastfeeding. These ﬁndings are consistent with those reported in
our previous review and clinical practice guideline6,8 and a
Cochrane review including neonates undergoing needle
procedures.89 Breastfeeding is a simple and cost-neutral
intervention that can be easily adopted across vaccination
settings by caregivers and health care professionals. It
provides analgesia through several mechanisms including
comfort (close proximity to the mother), distraction, and
stimulation of the orotactile and mechnoreceptors (sucking
on the breast),90 and presence of sweet-tasting substances in
the mother’s milk.91–93 Exclusive breastfeeding until 6
months is recommended by the World Health Organization
due to the nutritional and psychological beneﬁts of
breastfeeding; and supports breastfeeding for 2 years or
beyond.94 The analgesic eﬀects of breastfeeding further
Copyright
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promote breastfeeding as the method of choice for infant
feeding.
For the intervention to be eﬀective, an adequate latch
should be established before and continued during and
after the procedure. This may not be always possible to
achieve as the infant may be sleepy or not interested in
feeding or not hungry and an alternative pain management
strategy should be considered.

Breastfeeding Prevaccine Injection
If breastfeeding cannot be achieved during the procedure, breastfeeding prevaccine injection should be encouraged as it has some beneﬁts on distress secondary to satiation of the infant.34,35 There are no data regarding
breastfeeding before and during vaccine injections. It is
possible that breastfeeding before may cause less infants to
latch during the vaccine injections.

Topical Anesthetics
Topical anesthetics were eﬀective in reducing pain
associated with vaccine injections administered by various
routes including intramuscular and subcutaneous in children and adults. This conclusion was based on 17 studies
which predominantly used a comparator of placebo. In
terms of mechanism, topical anesthetics temporarily inhibit
the generation and transmission of pain impulses by
blocking the action potentials across nerve endings located
in the dermis.95 By producing dermal analgesia (topical
local anesthetics penetrate to a depth of ˜ 5 mm below the
skin surface), they eﬀectively reduce the pain from needle
puncture.
Despite their proven eﬀectiveness, topical anesthetics
are not used in clinical practice as part of standard care.
Topical anesthetics require an application time of 20 to
60 minutes depending on the commercial preparation that
is used. This is an obstacle to clinical use. However, if there
is insuﬃcient waiting time at the clinic, they can be applied
ahead of time. In 2 studies included in this review,38,48
instructions were provided to parents on how to apply the
cream at home on the day of vaccination. In the study by
Cassidy et al,38 54/161 (86%) of the parents applied the
topical anesthetic correctly and in the study by Taddio
et al,48 96/100 (96%) of the parents applied it correctly.
Further, 84/96 (88%) parents reported that they could ﬁt
the application of the cream in their schedules and 87 (91%)
reported that the cream was not diﬃcult to apply.48 Our
ﬁndings regarding the feasibility of home application is
consistent with other studies in which topical anesthetics
have been applied at home by parents before venipuncture
required for minor day care surgeries (eg, endoscopy)
provided optimal education was given.96,97 Two studies
reported on the mean waiting time before vaccine injection
in the clinics demonstrating feasibility of application of
topical anesthetics onsite. In the study by Abuelkheir et al36
(Saudi Arabia), the mean waiting time before the vaccine
injection was 57 minutes (SD = 16.7), whereas in the study
by Taddio et al98 (Canada), the mean waiting time reported
was 41.6 minutes (SD = 28.6). Application of the topical
anesthetics while awaiting the appointment is possible if
there is suﬃcient time. This also allows clinicians to assist in
their administration (eg, ensuring they are placed in the
correct anatomic location).
The cost of topical anesthetics requires some discussion. The cost of EMLA patch is BCanadian $12, while
the cost of a 60 g tube is B$50 which can be used for
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multiple applications. At present, individuals are usually
asked to absorb their cost. It is generally assumed that
individuals would not pay, however, there are some data
suggesting they would. In 1 included study, parents were
willing to pay $11.90 for topical anesthetics for future
injections.41 In another study by Ughasoro et al99 caregivers were willing to pay $8.31 for topical anesthetics
which is more that the cost of the cream itself.
Several practical issues should be addressed before its
adoption in clinical practice including: (1) ease of availability over the counter depending on geographic location
(eg, in USA topical anesthetics are available only if prescribed); (2) time to apply the topical anesthetics while
waiting for injection to be administered (wait times vary
between clinics); and (3) feasibility of parental education.
Therefore, helping parents plan for and advocate for proper
pain management ahead of time (eg, prescriptions for
topical anesthetics when availability in some geographical
regions is limited and educating parents), is critical for its
implementation in practice.
There is concern that concomitant use of topical
anesthetics during vaccination may lead to inactivation of
the vaccines or impair absorption due to its antimicrobial
activity.100–103 No interference by topical local anesthetics
were detected with the DPTaP-IPV-Hib, hepatitis B, or
Measles-Mumps-Rubella vaccines in any of the trials that
were included in this review (Table 5).43,44,46 The data are
consistent with studies performed in adults undergoing
Bacille-Calmette-Guérin vaccine administration.83 It is not
clear whether these results with topical anesthetics can be
generalized to other vaccine antigens; we suggest that testing for interactions between topical local anesthetics should
be incorporated in trials evaluating new vaccine antigens.
The use of topical anesthetics was associated with
transient local skin reactions such as pallor and erythema.

Sweet-tasting Solutions
We found suﬃcient evidence of beneﬁt from sucrose to
reduce pain response during vaccination.23,35,52–58,60–62,64–69
The majority of studies used sucrose in the concentration of
20% to 33% with a typical volume of 2 mL.35,55–58,61,62,67,69
The sucrose concentrations used ranged from 12% to 75%.
Also sucrose was administered 2 minutes before the procedure in majority of the studies.23,35,52,53,55–58,61,62,64–67,69
Our ﬁnding of a beneﬁcial eﬀect of sucrose for vaccine
injection pain is consistent with results of studies involving
other invasive skin-breaking procedures performed in
neonates and young infants such as heel lance and venipuncture.104 The mechanism of action of sucrose is
believed to include release of endogenous opioids and
distraction.105
A subgroup analysis based on the concentration of
sucrose demonstrated a consistent beneﬁt of concentrations
of 50% or 75% across all indicators of infant distress,
whereas the results were mixed with concentrations between
20% and 33%. Sucrose in the concentration of 12% was
not eﬀective in reducing any of the distress indicators. On
the basis of this analysis, sucrose in the dose of 2 mL with
concentrations >20% should be used for vaccine injection
pain.
Adverse events from sweet-tasting solutions such as
coughing and gagging were reported in only 1 trial,58
whereas no episodes of choking or any other adverse events
were reported in 2 other trials.60,64 None of these adverse
events were clinically signiﬁcant, as all infants recovered
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spontaneously within 10 seconds. More consistent documentation of the presence or absence of adverse events is
recommended in future research.
The eﬀectiveness of glucose was mixed and not as
robust as sucrose. Sucrose should be the preferred sweettasting solution, however, if not available glucose should be
considered as an alternative. Glucose solution for intravenous administration is easily available in clinical practice
in resource-limited countries and is a practical alternative to
sucrose for pain management. In settings where sweettasting solutions are not available, they can be prepared by
using 1 packet of table sugar mixed with 2 teaspoonfuls of
clean/sterile water; however, attention needs to be paid to
the use of clean/sterile water.

Vapocoolants
Vapocoolants are volatile liquids that when applied on
the skin provides transient anesthesia secondary to evaporation-induced skin cooling.106 The cold sensation may
reduce pain by gating pain signals so that cold is experienced rather than pain. The other proposed mechanism is
that they decrease the velocity of nerve impulse transmission across nerve ﬁbers.107 As vapocoolants cause
cooling and/or burning sensations on the skin, it can be
uncomfortable for some individuals including children who
may perceive it as a noxious stimulus.8
On the basis of the lack of evidence of beneﬁt, vapocoolants cannot be recommended for use in infants and
children. In a single study in adult population, vapocoolants were eﬀective in reducing pain associated with vaccine
injection.80 Vapocoolants are an attractive alternative to
topical anesthetics due to the short application time (s).
However, their application may be associated with discomfort because of the cold sensation that may be perceived as painful. In the included study, there was no report
of discomfort from vapocoolant application. In a recent
systematic review on venipuncture pain, the pain relief
provided by vapocoolants was oﬀset by the pain of their
application.108 As the cold sensation may be perceived
diﬀerently among individuals, their preferences should be
taken into consideration when oﬀering vapocoolants.

Oral Analgesics
No trials that evaluated oral analgesics (acetaminophen or ibuprofen) for vaccination pain were identiﬁed.
Evidence from other needle procedures showed no beneﬁt
of either acetaminophen or ibuprofen.81,82 More concerning is the recent data on the eﬀect of prophylactic
acetaminophen on immune response study to vaccination.86,88 The use of prophylactic paracetamol was
associated with reduction in antibody levels for several
vaccines evaluated including hepatitis B, DTPa + HBV +
IPV/Hib, and PHiD-CV.86,88 No data on the eﬀect of
prophylactic ibuprofen on immune response was identiﬁed.
Oral analgesics contain sweet-tasting solutions as ﬂavoring
agents and individuals may wish to oﬀer them for use
before vaccinations; however, sweet-tasting solutions such
as sucrose and glucose should be oﬀered instead because of
the potential to interfere with the vaccine response.

Two Versus One Intervention
There was evidence of a beneﬁt of the combination of
topical anesthetics and breastfeeding.42 There were no
additive beneﬁts of combining glucose and paciﬁer73 or
breastfeeding and sucrose.35 These data are limited to single
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studies with small sample sizes. In previous studies in
neonates, the combination of sucrose and paciﬁers has been
shown to work better than either alone.109

Strengths, Limitations, and Future Research
The major strength of this review is the availability of
large evidence base for some of the included interventions
(eg, breastfeeding, topical anesthetics in children, and
sweet-tasting solutions) and methodological rigor in terms
of blinding and quality of included studies. This results in
more conﬁdence in our conclusions. In addition, a meticulous approach that included both the GRADE and
Cochrane methodologies was used to conduct this systematic review and meta-analysis.
Methodologic challenges and limitations of this review
include the small sample sizes for some of the included
interventions (eg, vapocoolants across lifespan, topical anesthetics in adults, and oral analgesics) and limited age range of
the participants. Furthermore, many of these trials were
published before the Consolidated Standards of Reporting
Trials (CONSORT) guidelines110 were adopted. On the basis
of our review, areas for future research include: (1) evaluation
of the eﬀectiveness of expressed breast milk and bottle feeding (in babies whose parents choose to oﬀer bottle to provide
expressed breast milk or formula); (2) evaluation of the eﬀects
of topical anesthetics on immune response to newer vaccines
across lifespan; (3) studies to identify the optimal dose, concentration, and timing of administration of sweet-tasting
solutions; (4) additional studies on vapocoolants to conﬁrm
or refute its use in children and adults; and (5) combined
interventions compared with single active intervention with
the goal to reduce pain experienced to zero.
In summary, breastfeeding, topical anesthetics, and
sweet-tasting solutions are eﬀective interventions that can
be used in infants, children, and adults to reduce vaccine
injection pain. Despite the evidence regarding the eﬀectiveness of these interventions for >20 years, children and
adults around the world have not reaped the beneﬁts.
Rather than conducting eﬀectiveness/eﬃcacy studies for
well-studied, eﬀective interventions, it is time to conduct
implementation science research so that the use of these
interventions becomes the standard of care in clinical
practice globally. Educating our consumers (children,
parents, and adults undergoing vaccination) and health
care providers is crucial to make these changes. There is
some evidence that education of individuals can lead to
increased use.111
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